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Abstract
Background As novel systemic therapeutics for patients with atopic dermatitis (AD) are developed, ethical and
methodological concerns regarding placebo-controlled-trials (PCT) have surfaced.
Objective To guide the design and implementation of PCT in AD, focusing on trials with systemic medications.
Methods A subgroup of the International Eczema Council (IEC) developed a consensus e-survey, which was dissemi-
nated to IEC members.
Results The response rate was 43/82 (52%). Consensus was reached on 24/27 statements and on 3/11 options from
multiple-selection statements, including: performing monotherapy studies in proof-of-concept phases; avoiding con-
comitant topical corticosteroids or calcineurin inhibitors until a predeﬁned timepoint as rescue (borderline consensus);
selection of sites and assessors with recognized expertise in AD clinical trials; clear deﬁnition and identiﬁcation of base-
line disease severity; minimizing time and proportion of patients on placebo; using daily emollients with several options
provided; instigating open-label extension studies for enrolment after a predeﬁned timepoint; and including outcomes
which set a higher bar for disease clearance.
Conclusion Conducting PCT in AD requires balancing several, sometimes opposing principles, including ethics,
methodology, regulatory requirements and real-world needs. This paper can provide a framework for conducting PCT
with systemic medications for patients with AD.
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Introduction
With the emergence of novel therapeutics for patients with ato-
pic dermatitis (AD), there is a need to better define the optimal
study design for clinical trials. Studies including a placebo arm1
are the gold standard for studying safety and efficacy of novel
therapies at the proof-of-concept stage (phase Ib and IIa), fol-
lowed by phase IIb and pivotal phase III confirmatory trials for
inflammatory skin diseases such as AD. The placebo-controlled
trial (PCT) design poses methodological and ethical concerns in
AD trials. Recruiting and maintaining patients with moderate-
to-severe AD on placebo arms, when effective medications are
available, is one challenge. Patients on placebo whose active
medications are abruptly stopped weeks before the trials can
have a rebound effect, compromising retention in the trial.
However, the often-robust response in the placebo group
observed in AD when concomitant topical corticosteroids (TCS)
and/or calcineurin inhibitors (TCI) are used in a clinical trial
setting may reduce the difference between the active and placebo
group.2,3 To address these issues, a group of councilors and asso-
ciates of the International Eczema Council (IEC), an
organization of international experts on AD, conferred to pro-
vide practice recommendations for the design and execution of
PCT with systemics for AD.
Materials and methods
Authors participated in online discussions to delineate topics of
interest and subsequently developed a consensus e-survey,
approved by all authors, which was disseminated to the IEC
membership between 21 February 2018 and 12 March 2018
(SurveyMonkey Inc., San-Mateo, CA, USA; www.surveymonke
y.com). The survey consisted of 27 statements followed by a
5-point Likert response (from ‘strongly agree’ to ‘strongly dis-
agree’) and two statements with multiple-check options. Con-
sensus was reached when <30% of voters disagreed (i.e. no more
than 30% marked ‘strongly disagree’ or ‘disagree’).4
Results
The survey response rate was 43/82(52%). Consensus was
reached on 24/27 statements and on 3/11 multiple-selection
options (Table 1, Appendices S1 and S2). An overview of PCT
in AD is presented below, followed by the IEC consensus.
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Scientiﬁc rationale for placebo controls
Since the first use of a placebo in the 1930s,5 inclusion of place-
bos as controls has become the gold standard of comparator tri-
als. PCT are proposed to control for the placebo effect: the effect
of receiving treatment, even a biologically inert one. They also
control for other factors that can influence study outcomes and
are not related to the pharmacologic properties of the study
drug, such as regression to the mean and the change in beha-
viour when people are monitored closely.6 Specific to dermatol-
ogy trials, changes in daily skin care routine such as moisturizing
can also influence the disease.
Placebo-controlled-trials provide direct evidence for the effi-
cacy of the study drug. This contrasts with active-control trials
(ACT), which rely on evidence of the efficacy of the active con-
trol from prior studies, to interpret the efficacy of the study
drug.7 PCT also enable measuring the pharmacological effect of
a study drug by itself, rather than only the relative effect com-
pared with another treatment.1
Ethical considerations
The use of placebo as a comparator in AD has long evoked con-
troversy. Patients randomized to placebo may not receive stan-
dard-of-care, effective treatment.5 Consequently, AD patients
with intractable itch, sleep loss and reduced quality of life would
be left untreated for extended periods of time.8–11 The World
Medical Association Declaration of Helsinki promotes ACT as
the design of choice, with PCT considered only with a robust sci-
entific methodological justification and when patients do not
face severe risks, as most would consider is the case of AD.12
Regulatory issues
Drug studies are often designed to meet requirements of health
authorities worldwide. Guidance and position papers from these
agencies place a significant emphasis on the scientific need for
placebo controls6,13 and indeed The US Food and Drug Admin-
istration (FDA) and the Japan Pharmaceuticals and Medical
Devices currently require placebo controls in AD pivotal trials
that support a marketing authorization application. The Euro-
pean Medicines Agency (EMA) presents a similar approach14
and also often requires either an active control or enrolment of
patients who have failed an approved systemic treatment for
AD.15
Practical considerations
Patients and investigators can be reluctant to participate in stud-
ies with a placebo arm. This is particularly important in trials of
systemic agents for AD, in which patients may have a consider-
able symptom burden. Studies regularly require participants to
be off medications for a washout period prior to baseline, fur-
ther prolonging the time off therapy and often profoundly wors-
ening disease severity. As safer and more effective treatments
become available, recruitment for PCT in AD could prove
difficult. This could lead to selection bias, with preferential
recruitment of patients with more severe and recalcitrant disease
who have failed numerous prior treatment options. Although
these patients may have low placebo responses, they may also
display delayed or diminished responses to the study drug,
underestimating its efficacy. Alternatively, patients na€ıve to sys-
temic therapy or with milder disease may be more likely to be
recruited, as they may better tolerate placebo treatment or
because they failed to qualify for reimbursement for a new ther-
apy for AD. These patients may have enhanced placebo
responses.
The placebo effect in atopic dermatitis clinical trials
There are limited data on the actual effect of placebo on out-
comes in AD. A meta-analysis of randomized controlled trials
(RCT) found a clinically modest but statistically significant pla-
cebo effect on itch in patients with AD on systemic medications,
although trials with concomitant topical treatments were
included.16 Recent AD RCT offer insights on the placebo effect
on other outcomes in AD. Pooled data of 575 patients on pla-
cebo from studies of dupilumab in moderate-to-severe AD with-
out concomitant TCS17–19 demonstrate a 31% improvement
from baseline Eczema Area and Severity Index (EASI) and a
13% EASI-75 response at weeks 12–16, much higher than pla-
cebo arm responses in studies on biologics for psoriasis (average
PASI-75 of 4%).20 While a plethora of factors contributes to the
high placebo responses in AD as compared to psoriasis, an
important factor may be that AD is more difficult to quantify
clinically. Psoriasis lesions are typically well demarcated and
markedly thickened, but AD lesions are often flatter and tend to
blend with non-lesional skin.
Drivers and predictors of the placebo response in AD
The placebo response in trials of systemic medications for AD is
likely multifactorial. The placebo may offer some true therapeu-
tic properties in AD, more so with outcomes that depend on
patient perception, such as itch. Frequent visits and better edu-
cation about skin care could also play a role in high placebo
responses.21,22 Improvement could reflect the natural history of
AD, or that some patients are more prone to participate in a trial
when their disease is at its peak.
However, some of the effects observed in the placebo arms of
AD RCT are related to the design and implementation of a
study, rather than a true placebo effect. It is important to ensure
that when a study drug fails to demonstrate superiority to pla-
cebo, it means that the drug lacks clinically significant efficacy,
rather than that the study was unable to distinguish an effective
treatment from placebo.1 Some factors to consider include:
1 Inclusion of patients with milder disease in studies designed
for patients with moderate-to-severe disease can artificially
enrich the placebo response. The assessment of patients with
AD is complex, as highlighted in a recent IEC consensus
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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Table 1 Results of the International Eczema Council consensus survey†
Topic Statement Proportion (%)
of respondents
marking ‘disagree’/‘
strongly disagree’
Investigational sites PCT should be conducted by centres with recognized expertise in dermatology clinical trials 1/43 (2)
PCT should be conducted by centres with recognized speciﬁc expertise in AD clinical trials 3/43 (7)
Clinical assessments should be performed by (more than one answer can apply)‡
Dermatologists with clinical and research expertise in AD 5/43 (12)
Dermatologists with experience treating AD but no special expertise 22/43 (51)
Physicians under direct supervision of Dermatologists with clinical and research expertise in
AD
22/43 (51)
Any dermatologist (e.g. Including Dermatologists that do not have a signiﬁcant medical
dermatology practice)
42/43 (98)
Non-dermatologists 40/43 (93)
Study design Monotherapy studies (studies where patients receive only one active treatment in addition to
emollients) are recommended in proof-of-concept studies
3/43 (7)
Active comparator studies are recommended following monotherapy phase 3 PCT 1/42 (2)
Active comparator studies are recommended parallel to monotherapy phase 3 PCT 5/43 (12)
For moderate-to-severe AD patients the duration of treatment with placebo should be reduced
as much as possible
2/43 (5)
For moderate-to-severe AD patients the proportion of patients receiving placebo should be
reduced as much as possible
2/43 (5)
The interval between assessments should verify that patients with poorly controlled disease are
identiﬁed
0/42 (0)
PCT in AD should comply with general principles of PCT to ensure double blinding of placebo
vs. drug for patient and study staff members (e.g. similar look, similar taste of placebo and drug if
oral; similar feel if placebo and drug are injected)
0/43 (0)
It is key to educate participants to adhere to the clinical trial protocol and avoid using off-protocol
treatments
0/43 (0)
Inclusion/exclusion Studies requiring failure of TCS/TCI should clearly deﬁne and document failure in the study
protocol to standardize patient selection
1/43 (2)
The protocol on TCI/TCS failure requirements should specify: (more than answer can apply)‡
Minimal potency of TCS/TCI used 9/43 (21)
TCS length of use 9/43 (21)
TCS quantity per unit time such as grams per day or week 22/43 (51)
Time before ﬂares typically occur upon TCS discontinuation 19/43 (44)
TCS side effects 24/43 (56)
No speciﬁcation necessary 39/43 (91)
Open-label extension Open-label extension studies following PCT are recommended 0/43 (0)
PCT should deﬁne a minimal time after initiation for dropout after which patients can enter an
open-label extension study
2/43 (5)
Emollient use in trials Emollients should be used in both study and placebo arms daily/twice daily 1/43 (2)
A choice of several emollients should be provided by company/study to standardize emollient
use
5/43 (12)
Both cream and ointment emollients should be made available for patients to choose 8/43 (19)
Emollient should be reimbursed by the company 0/43 (0)
Propylene glycol-free emollients should be available 3/43 (7)
Fragrance-free emollients should be available 0/43 (0)
No prescription emollient should be used 9/43 (21)
Concomitant TCS/TCI Phase 1, 2 and 3 pivotal trials should not allow the use of concomitant TCS/TCI in protocol at all 23/43 (53)
Phase 1, 2 and 3 pivotal trials should not allow the use of concomitant TCS/TCI in protocol until
a predeﬁned timepoint as rescue medications
12/43 (28)
Phase 1, 2 and 3 pivotal trials should allow concomitant TCS/TCI in protocol at all timepoints 20/43 (47)
Patients will be considered non-responders after TCS/TCI rescue 19/43 (44)
If rescue with TCS/TCI is allowed, the amount, potency and frequency of rescue medications
used should be monitored and quantiﬁed and could be recorded as a secondary end point
0/43 (0)
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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statement endorsing a systematic and holistic approach to
identifying patients who warrant systemic treatment.23 Cor-
rect identification of patients who are suitable for trials of
systemic medications requires AD-related clinical expertise,
and may be difficult for sites that are less familiar with AD
patients and not well versed with disease assessments. Eligi-
bility creep, described as the tendency for patients to meet eli-
gibility criteria when they are close yet not meeting
eligibility,24 can skew recruitment towards patients with
milder disease. Centres which are not specialist dermatology
departments may have less access to severe patients, which
could promote the latter phenomenon.
2 Concomitant TCS or TCI. Current AD treatment guidelines
recommend a step-up approach from trigger avoidance and
emollients, to TCS,25–27 and then to phototherapy and sys-
temic medications.23 In practice, patients often use topical
medications in conjunction with systemic therapy. To make
it easier for participating patients, better reflect ‘real-world’
treatment patterns, and study potential synergistic effects of
combination topical and systemic therapy, some trials assess
systemic therapy in AD with concomitant use of TCS/TCI.
However, such combination therapy studies confer additional
layers of complexity for study design and interpretation.
TCS/TCI can affect study outcomes at both the clinical and
molecular levels.2,3,28–30 In patients with moderate-to-severe
AD, a phase 3 trial of dupilumab vs. placebo with concomi-
tant TCS29 demonstrated higher responses for both placebo
and dupilumab arms than similar phase 3 trials without
TCS17 (Table 2). The absolute difference in efficacy between
the placebo and active arms was unchanged by TCS, indicat-
ing the power to detect a difference between dupilumab and
placebo was preserved in these studies. However, recent stud-
ies of lebrikizumab and tralokinumab in moderate-to-severe
AD patients with mandated TCS use found much higher pla-
cebo responses than the dupilumab studies, up to 60% EASI-
50 and 34% EASI-75 responses.2,3 Detecting drug efficacy
with such elevated placebo responses is difficult.
3 The course of AD is impacted by multiple environmental
influences.31–34 Some studies have shown that AD prevalence
decreases in geographic locations with increased sun expo-
sure and warmer temperatures,35,36 although others have
demonstrated these factors are associated with poorly con-
trolled AD.37 The effect of humidity on AD prevalence has
also produced conflicting results.35,36 While the placebo
response may be affected by geographical location and sea-
sonality, environmental effects can be difficult to harmonize
across studies.
IEC statement on PCT with systemic medications for AD
The IEC recommendations (summarized in Fig. 1) are based on
the survey consensus statements (in italic) and group discus-
sions.
1 Monotherapy studies (in which patients receive only one active
treatment in addition to emollients) are recommended in
proof-of-concept studies.
2 The inclusion of concomitant TCS/TCI in protocol in phase 1,
2 and 3 pivotal trials was controversial. Disallowing TCS/TCI
until a predefined timepoint as rescue medications reached bor-
derline consensus with 28% of respondents disagreeing. Even
more disagreed with either completely prohibiting TCS/TCI in
pivotal studies (53%) or, alternatively, allowing them at all
timepoints (47%). This controversy probably reflects two
opposing problems: strict and prolonged prohibition of TCS/
TCI during trials risks selecting against patients with severe
AD, consequently elevating the placebo response. Conversely,
permissive TCS/TCI use can also raise the placebo response.
Minimizing TCS/TCI washout to 1–2 weeks and allowing
Table 2 Absolute difference and relative improvements (ex-
pressed as relative risks; RR) of dupilumab vs. placebo in phase 3
trials
Intervention EASI50 EASI75 EASI90 IGA0/1
Monotherapy (SOLO 1 & SOLO 2)17
Dupilumab (n = 919) 64% 49% 32% 37%
Placebo (n = 460) 23% 13% 7% 9%
Absolute difference 41% 36% 25% 28%
RR 2.8 3.7 4.4 4
Concomitant TCS (Chronos)29
Dupilumab (n = 425) 79% 65% 42% 39%
Placebo (n = 315) 37% 23% 11% 12%
Absolute difference 43% 42% 31% 27%
RR 2.1 2.8 3.8 3.2
Table 1 Continued
Topic Statement Proportion (%)
of respondents
marking ‘disagree’/‘
strongly disagree’
Outcome measures and analysis Trials should include outcomes which set a higher bar for disease clearance such as IGA0/1 and
EASI-90 to mitigate the placebo response
8/43 (19)
Analysis should include both change from baseline and proportion of responders 0/43 (0)
†Statements reaching consensus are marked in grey (i.e. no more than 30% marked ‘strongly disagree’ or ‘disagree’). ‡Multiple option questions had ‘agree/
disagree’ options only. The proportion (%) of respondents marking ‘agree’ is displayed.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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rescue TCS/TCI at the earliest timepoint possible, depending
on drug mechanism and expected time to effect, can address
these concerns in part.
3 If rescue with TCS/TCI is allowed, the amount, potency and
frequency of rescue medications used should be monitored and
quantified and could be recorded as a secondary end point.
Rescue
Rescue
• Monotherapy studies for phase 1,2, and early 3 trials
• TCS/TCI not allowed in protocol until a predefined 
timepoint as rescue
• The use of rescue medications should be recorded 
as a secondary endpoint
• Active treatment arms studies parallel to and/or 
following phase 3 PCT
Center with expertise in AD 
research
Assessments by dermatologists with 
expertise in AD*
Well defined inclusion criteria 
emphasizing baseline disease 
severity
Specify TCS/TCI failure including 
minimal used potency and length of 
time used**
Minimal possible duration, defined 
per medication
OLE
• Include outcomes with higher bars 
for clearance such as IGA 0/1 and 
EASI-90
• Include both change from baseline 
and proportion of responders in 
analysis
• Comply with general PCT principles
• Educate patients on adherence to protocol
• Minimize duration on placebo
• Reduce proportion of patients on placebo (consider 
unbalanced randomization)
• The interval between assessments should enable 
identifying patients with poorly controlled disease.
Emollients
• Use for both study arms daily
• Provide a choice of several emollients, both cream 
and ointment, propylene-glycol and fragrance free. 
No prescription emollient.
Control arm
Site selection
Outcomes
Not eligible for OLE
Limited safety data
Early dropout
Screening
Washout
Intervention
phase
Eligible for OLE
Adequate safety and 
efficacy data
Dropout after predefined timepoint
Eligible for OLE
Complete safety and 
efficacy data for analysis
Completed study
Figure 1 The approach to placebo-controlled trials of systemic medications for atopic dermatitis. AD, atopic dermatitis; EASI-90, a 90%
improvement from the baseline Eczema Area and Severity Index score; IGA 0/1, Investigator Global Assessment of clear or almost clear;
OLE, open label extension; PCT, placebo-controlled trial; TCS, topical corticosteroids; TCI, topical calcineurin inhibitor; *Less favorable
options for assessors: Dermatologists with experience treating AD and physicians under the direct supervision of AD experts, **Possibly
specify TCS/TCI quantity, time to ﬂare upon TCS/TCI discontinuation and TCS side effects.
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4 Active treatment arms studies are recommended parallel to
and/or following phase 3 PCT.
5 Selection of sites with recognized expertise in AD management
and testing of therapeutics should be encouraged to assure that
the right patients, inclusion criteria and assessments are
implemented, as well as having Dermatologists with clinical
and research experience in AD performing clinical assessments.
6 An emphasis should be placed on correct identification of
the participants’ baseline disease severity, which should be
clearly defined using validated outcomes after a period of
adequate treatment, defined individually per treat-
ment.23,25,38
7 Studies requiring TCS/TCI failure for inclusion should clearly
define and document failure in the study protocol to standard-
ize patient selection including the minimal potency and length
of time used.
8 PCT in AD should comply with PCT design principles, e.g.:
the physical qualities of the placebo should be as identical as
possible to the study drug.
9 Educating participants to adhere to the clinical trial protocol
and limit placebo arm patients from using active treatment is
key to measuring the true placebo effect.
10 For moderate-to-severe AD patients, the duration of treatment
with placebo and the proportion of patients receiving placebo
should be reduced as much as possible. The washout period
prior to intervention should also be as short as possible,
defined per medication.
11 The interval between assessments should verify that patients
with poorly controlled disease are identified.
12 While emollients are much less effective in alleviation of
moderate-to-severe AD signs and symptoms than TCS/TCI,
they still demonstrate some efficacy.21,30,39 It is recom-
mended to provide emollients and encourage all patients to
use them daily in clinical trials. To enhance acceptability a
choice of several emollients and both cream and ointment
emollients should be made optional for patients; minimizing
irritants and allergens is recommended, e.g. providing fra-
grance-free and propylene glycol-free emollients (low concen-
trations of propylene glycol can sometimes be added to
enhance penetration of emollient ingredients). It is impera-
tive that the vehicle, frequency, quantity and duration
applied are defined and standardized within a study, avoid-
ing more sophisticated (prescription) emollient formulations.
Some emollients have detrimental effects in AD40 and
should be avoided.
13 Ensure that patients on placebo are able to enrol in open-label
extension (OLE) studies, even when they drop out in the
double-blind component of a study. A minimal time after
initiation for dropout after which patients can enter an OLE
should be predefined, taking into account the onset of action
of the experimental treatment. The criteria for dropping out
should be well-specified to minimize premature
discontinuation with the promise of relief through rescue or
open-label administration. Early loss of placebo patients
could impair the evaluation of long-term effectiveness in the
placebo arm.
14 Trials should include outcomes which set a higher bar for dis-
ease clearance such as IGA0/1 and EASI-90. Pooling patients
from the dupilumab phase 3 studies, we observed that both
with and without concomitant TCS, as the bar for efficacy is
lowered from IGA 0/1 and EASI-90 towards EASI-50, pla-
cebo responses increase proportionally more than the drug
arm responses (Table 2). It is possible that inclusion of
more stringent definitions of treatment success can mitigate
placebo responses, although additional studies need to cor-
roborate this observation. Inclusion of less stringent out-
comes is also advised as it allows for a more complete
representation of treatment responses.
15 The Harmonizing Outcome Measures in Eczema (HOME)
group selected the EASI and the Patient-Oriented Eczema
Measure (POEM) as the preferred measures of AD signs
and symptoms in clinical trials of AD, and published recom-
mendations on standardized reporting of these measures.41–
43 However, best practices for analysing these outcomes are
not clearly established. We recommend including both change
from baseline and proportion of responders in the analysis.43
16 As the placebo response may be increased in patients with
moderate vs. severe disease,44 performing a planned sub-
group analysis by disease severity could aid in understand-
ing the differential effect of both study drug and placebo on
these patient populations.45 However, this analysis requires
sufficient patients with severe disease.
Limitations
This consensus is limited by the relative lack of research on the
predictors of the placebo response in AD. A higher survey
response rate would have been preferable, although our 52% rate
was similar to other recent IEC surveys. The IEC is composed of
experts dedicated to the treatment and research of AD, which
could have affected the conclusions regarding the optimal setup
for AD clinical studies.
Conclusion
Balancing ethics, scientific rigour, practical and regulatory con-
cerns in PCT with systemic treatments for AD is challenging.
Concomitant use of TCS facilitates inclusion of more severely
affected AD subjects but raises the placebo rate. On the other
hand, long TCS washout periods and avoidance of TCS during
trials select for subjects with milder AD and also risks a higher
placebo response. This article provides an outline of the multiple
considerations involved in the design and implementation of
such trials, further stressing the importance of using sites and
investigators well versed in AD research and care who are able to
enroll a more severe AD population. As the therapeutic landscape
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
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of AD evolves, the balance between these principles may shift,
and a dynamic and critical approach when designing PCT is
advised. Future work is needed to fill in the gaps highlighted in
this paper and to better delineate the placebo effect on different
outcomes in AD. This paper can serve as a basis for discussions
and research on the use of placebo in other fields in dermatology.
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